ClinicalTrials.gg

Program

iloperidone

Also written as “Iloperidone”, “Iloperidone 1 MG” and “iloperidone (oral tablet)”.

Its studies are mostly in Schizophrenia · Hypertension · Parkinson Disease, led by 4 companies.

Furthest: phase 4, since Dec 5, 202215 company-led studies, 3 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vanda Pharmaceuticals103 open or runningphase 4since Dec 5, 2022Nov 10, 2005Nov 2027phase 3 · NCT06961968
CSPC Pharmaceutical Group20 open or runningphase 3since May 19, 2015May 19, 2015none ahead
Novartis20 open or runningphase 4since Sep 19, 2010Sep 19, 2010none ahead
Hansoh Pharmaceutical Group10 open or runningphase 2since Jun 17, 2012Jun 17, 2012none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Nov 10, 2005.

  1. Feb 3, 2011Phase 3 study in SchizophreniaVanda Pharmaceuticals · NCT01291511 · 635 enrolled · United States, India, Ukraine
  2. Aug 31, 2011Phase 1 study in SchizophreniaVanda Pharmaceuticals · NCT01495169 · 33 enrolled · United States
  3. Sep 23, 2011Phase 1 study in Hepatic ImpairmentNovartis · NCT01529294 · 90 enrolled · United States
  4. Jun 17, 2012Hansoh Pharmaceutical Group's first study: phase 2 study in SchizophreniaNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT01623713 · 260 enrolled · China
  5. May 19, 2015CSPC Pharmaceutical Group's first study: phase 3 study in SchizophreniaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT02453893 · 288 enrolled · China
  6. Jan 19, 2018Phase 1 study in BioequivalenceCSPC Pharmaceutical Group · NCT03420534 · 36 enrolled · China
  7. Oct 7, 2019Phase 1 study in SchizophreniaVanda Pharmaceuticals · NCT04127058 · 12 enrolled · United States
  8. Jan 13, 2021Phase 1 study in SchizophreniaVanda Pharmaceuticals · NCT04712734 · 42 enrolled · United States
  9. Mar 24, 2021Phase 3 study in Bipolar I DisorderVanda Pharmaceuticals · NCT04819776 · 417 enrolled · United States, Bulgaria, Poland
  10. Apr 18, 2022Phase 2 study in Parkinson Disease PsychosisVanda Pharmaceuticals · NCT05344365 · United States
  11. Dec 5, 2022Phase 4 study in SchizophreniaVanda Pharmaceuticals · NCT05648591 · 100 planned · United States
  12. Apr 29, 2025Phase 3 study in SchizophreniaVanda Pharmaceuticals · NCT06961968 · 400 planned · United States
  13. Jul 22, 2025Phase 2 study in HypertensionVanda Pharmaceuticals · NCT07090161 · 240 planned · United States
  14. Oct 1, 2026Primary completion moved from 2026-03-31 to 2028-12-31Date moved laterphase 4 · +33 months · NCT05648591

Ahead

  1. Nov 2027Primary completion: phase 3 study in SchizophreniaVanda Pharmaceuticals · NCT06961968
  2. Dec 31, 2028Primary completion: phase 4 study in SchizophreniaVanda Pharmaceuticals · NCT05648591

TargetBeta

DRD2 →HTR2A →read by rule
“Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
paliperidoneruleJohnson & Johnsonphase 4106
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
lurasidoneruleSumitomo Pharmaphase 452
lumateperoneruleJohnson & Johnsonphase 325

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07090161Hypertension · United States2RecruitingVanda PharmaceuticalsOct 2026240
NCT06961968Schizophrenia · United States3RecruitingVanda PharmaceuticalsNov 2027400
NCT05648591Schizophrenia · United States4RecruitingVanda PharmaceuticalsDec 31, 2028100
NCT05344365Parkinson Disease Psychosis · United States2WithdrawnVanda PharmaceuticalsNov 20230
NCT04819776Bipolar I Disorder · United States, Bulgaria, Poland3CompletedVanda PharmaceuticalsSep 7, 2022417
NCT04712734Schizophrenia · United States1CompletedVanda PharmaceuticalsAug 30, 202242
NCT04127058Schizophrenia · United States1CompletedVanda PharmaceuticalsNov 27, 201912
NCT03420534Bioequivalence · China1UNKNOWNCSPC Pharmaceutical GroupDec 14, 201736
NCT02453893Schizophrenia · China3UNKNOWNCSPC Pharmaceutical GroupJun 2015288
NCT01623713Schizophrenia · China2CompletedHansoh Pharmaceutical GroupOct 2013260
NCT01529294Hepatic Impairment · United States1CompletedNovartisJul 201290
NCT01495169Schizophrenia · United States1CompletedVanda PharmaceuticalsFeb 201533
NCT01291511Schizophrenia · United States, India, Ukraine3CompletedVanda PharmaceuticalsMar 2014635
NCT01207414Schizophrenia · United States4CompletedNovartisJan 2012501
NCT00254202Schizophrenia · United States, India3CompletedVanda PharmaceuticalsSep 26, 2006593

How it is read

Names in the registry

  • “Iloperidone”, 9 entries
  • “iloperidone”, 4 entries
  • “Iloperidone 1 MG”, 1 entry
  • “iloperidone (oral tablet)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.